ACUT
AccuStem Sciences, Inc.
Price Chart
Latest Quote
$0.23
+0.03 (+12.20%)
Current Price
| Previous Close | $0.20 |
| Open | $0.23 |
| Day High | $0.23 |
| Day Low | $0.23 |
| Volume | 108 |
Stock Information
| Shares Outstanding | 16.07M |
| Cash Equivalents | $12K |
| Net Income | $-1.80M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.70M |
| EPS (TTM) | $-0.12 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.68M |
| Income | $-1.80M |
| Book/sh | $-0.24 |
| Cash/sh | $0.00 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 0.00 |
| Current Ratio | 0.01 |
Returns & Margins
| ROA | -72.64% |
Ownership
| Insider Ownership | 50.92% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.95 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.19 |
| SMA50 | $0.24 |
| SMA200 | $0.59 |
| RSI | 53.80 |
| ATR | 0.0341 |
| Shares Float | 11.43M |
| Volatility | 1.88 |
| Rel Volume | 0.03 |
Performance History
| Week | +21.63% |
| Month | -0.69% |
| Quarter | -34.27% |
| 6 Months | -67.14% |
| YTD | -71.73% |
| Year | -73.86% |
| 3 Years | -73.32% |
| 10 Years | -88.50% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-20 | $0.23 | 183 |
| 2026-07-17 | $0.20 | 0 |
| 2026-07-16 | $0.20 | 126 |
| 2026-07-15 | $0.18 | 19,926 |
| 2026-07-14 | $0.22 | 9,034 |
| 2026-07-13 | $0.19 | 0 |
| 2026-07-10 | $0.19 | 5,126 |
| 2026-07-09 | $0.16 | 0 |
| 2026-07-08 | $0.16 | 398 |
| 2026-07-07 | $0.17 | 0 |
| 2026-07-06 | $0.17 | 21,628 |
| 2026-07-02 | $0.16 | 8,912 |
| 2026-07-01 | $0.16 | 58,341 |
| 2026-06-30 | $0.29 | 1,480 |
| 2026-06-29 | $0.20 | 0 |
| 2026-06-26 | $0.20 | 0 |
| 2026-06-25 | $0.20 | 0 |
| 2026-06-24 | $0.20 | 3,114 |
| 2026-06-23 | $0.21 | 0 |
| 2026-06-22 | $0.21 | 11,716 |
About AccuStem Sciences, Inc.
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on ACUT.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Total Expenses | $1,505,102 | $2,050,664 | $3,746,419 |
| Operating Expense | $1,505,102 | $2,050,664 | $3,746,419 |
| General And Administrative Expense | $1,366,778 | $1,911,001 | $3,479,486 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Normalized Income | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income From Continuing And Discontinued Operation | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Total Operating Income As Reported | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income Common Stockholders | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income Including Noncontrolling Interests | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Income Continuous Operations | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Pretax Income | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Operating Income | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Per Share | |||
| Diluted EPS | $-0.13 | $-0.18 | $-0.34 |
| Basic EPS | $-0.13 | $-0.18 | $-0.34 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,501,472 | $-2,047,034 | $-3,743,098 |
| Reconciled Depreciation | $3,630 | $3,630 | $3,321 |
| EBITDA (Bullshit earnings) | $-1,501,472 | $-2,047,034 | $-3,743,098 |
| EBIT | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Diluted Average Shares | $11,435,362 | $11,346,535 | $11,016,165 |
| Basic Average Shares | $11,435,362 | $11,346,535 | $11,016,165 |
| Diluted NI Availto Com Stockholders | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Tax Provision | $0 | $0 | $0 |
| Research And Development | $138,324 | $139,663 | $266,933 |
| Selling General And Administration | $1,366,778 | $1,911,001 | $3,479,486 |
| Other Gand A | $1,366,778 | $1,911,001 | $3,479,486 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-3,313,224 | $-2,111,580 | $-139,550 |
| Total Assets | $50,851 | $133,897 | $939,689 |
| Total Non Current Assets | $418 | $4,048 | $7,678 |
| Current Assets | $50,433 | $129,849 | $932,011 |
| Prepaid Assets | $45,387 | $108,368 | $168,430 |
| Cash Cash Equivalents And Short Term Investments | $5,046 | $21,481 | $733,978 |
| Cash And Cash Equivalents | $5,046 | $21,481 | $733,978 |
| Cash Financial | $5,046 | $21,481 | $733,978 |
| Other Current Assets | - | - | $29,603 |
| Debt | |||
| Net Debt | $20,102 | $34,198 | - |
| Total Debt | $25,148 | $55,679 | $106,551 |
| Current Debt And Capital Lease Obligation | $25,148 | $55,679 | $106,551 |
| Current Debt | $25,148 | $55,679 | $106,551 |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $3,364,075 | $2,245,477 | $1,079,239 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 |
| Current Liabilities | $3,364,075 | $2,245,477 | $1,079,239 |
| Current Notes Payable | $25,148 | $55,679 | $106,551 |
| Payables And Accrued Expenses | $3,338,927 | $2,189,798 | $972,688 |
| Payables | $3,174,874 | $2,033,364 | $454,063 |
| Accounts Payable | $804,615 | $578,378 | $311,834 |
| Equity | |||
| Common Stock Equity | $-3,313,224 | $-2,111,580 | $-139,550 |
| Total Equity Gross Minority Interest | $-3,313,224 | $-2,111,580 | $-139,550 |
| Stockholders Equity | $-3,313,224 | $-2,111,580 | $-139,550 |
| Retained Earnings | $-8,027,047 | $-6,521,945 | $-4,471,281 |
| Other | |||
| Ordinary Shares Number | $12,100,535 | $11,346,535 | $11,346,535 |
| Share Issued | $12,100,535 | $11,346,535 | $11,346,535 |
| Tangible Book Value | $-3,313,224 | $-2,111,580 | $-139,550 |
| Invested Capital | $-3,288,076 | $-2,055,901 | $-32,999 |
| Working Capital | $-3,313,642 | $-2,115,628 | $-147,228 |
| Total Capitalization | $-3,313,224 | $-2,111,580 | $-139,550 |
| Additional Paid In Capital | $4,701,723 | $4,399,019 | $4,320,385 |
| Capital Stock | $12,100 | $11,346 | $11,346 |
| Common Stock | $12,100 | $11,346 | $11,346 |
| Preferred Stock | $0 | $0 | $0 |
| Current Accrued Expenses | $164,053 | $156,434 | $518,625 |
| Dueto Related Parties Current | $2,370,259 | $1,454,986 | $142,229 |
| Net PPE | $418 | $4,048 | $7,678 |
| Accumulated Depreciation | $-10,581 | $-6,951 | $-3,321 |
| Gross PPE | $10,999 | $10,999 | $10,999 |
| Machinery Furniture Equipment | $10,999 | $10,999 | $10,999 |
| Treasury Shares Number | - | $0 | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-664,066 | $-1,615,643 | $-1,817,052 |
| Operating Activities | |||
| Operating Cash Flow | $-664,066 | $-1,615,643 | $-1,806,053 |
| Cash Flow From Continuing Operating Activities | $-664,066 | $-1,615,643 | $-1,806,053 |
| Operating Gains Losses | - | - | $-66,981 |
| Investing Activities | |||
| Investing Cash Flow | $0 | $0 | $-10,999 |
| Cash Flow From Continuing Investing Activities | $0 | $0 | $-10,999 |
| Capital Expenditure | - | - | $-10,999 |
| Financing Activities | |||
| Issuance Of Capital Stock | $0 | $0 | $2,675,940 |
| Financing Cash Flow | $647,632 | $903,146 | $2,551,030 |
| Cash Flow From Continuing Financing Activities | $647,632 | $903,146 | $2,551,030 |
| Net Other Financing Charges | $781,077 | $1,246,757 | $204,879 |
| Net Common Stock Issuance | $0 | $0 | $2,675,940 |
| Common Stock Issuance | $0 | $0 | $2,675,940 |
| Other | |||
| Repayment Of Debt | $-133,445 | $-343,611 | $-338,258 |
| Interest Paid Supplemental Data | $3,392 | $7,192 | $7,474 |
| End Cash Position | $5,047 | $21,481 | $733,978 |
| Beginning Cash Position | $21,481 | $733,978 | $0 |
| Changes In Cash | $-16,434 | $-712,497 | $733,978 |
| Proceeds From Stock Option Exercised | $0 | $0 | $8,469 |
| Net Issuance Payments Of Debt | $-133,445 | $-343,611 | $-338,258 |
| Net Short Term Debt Issuance | $-133,445 | $-343,611 | $-338,258 |
| Short Term Debt Payments | $-133,445 | $-343,611 | $-338,258 |
| Net PPE Purchase And Sale | $0 | $0 | $-10,999 |
| Purchase Of PPE | $0 | $0 | $-10,999 |
| Change In Working Capital | $533,948 | $352,757 | $1,870,137 |
| Change In Other Current Assets | $0 | $29,603 | $-29,603 |
| Change In Payables And Accrued Expense | $368,053 | $-19,968 | $275,675 |
| Change In Accrued Expense | $7,620 | $-352,512 | $401,130 |
| Change In Payable | $360,433 | $332,544 | $-125,455 |
| Change In Account Payable | $226,237 | $266,544 | $-76,846 |
| Change In Prepaid Assets | $165,895 | $343,122 | $270,692 |
| Change In Receivables | $0 | $0 | $1,353,373 |
| Stock Based Compensation | $303,458 | $78,634 | $133,889 |
| Depreciation Amortization Depletion | $3,630 | $3,630 | $3,321 |
| Depreciation And Amortization | $3,630 | $3,630 | $3,321 |
| Depreciation | $3,630 | $3,630 | $3,321 |
| Net Income From Continuing Operations | $-1,505,102 | $-2,050,664 | $-3,746,419 |
| Net Foreign Currency Exchange Gain Loss | - | $0 | $-66,981 |
Fetched: 2026-02-02